Changes

Jump to navigation Jump to search

Moderna v. Pfizer (view source)

Revision as of 02:08, January 11, 2023

1,066 bytes added ,  02:08, January 11, 2023
→‎Moderna's Allegations
Line 15: Line 15:  
protein needed for a particular disease. This makes mRNA medicines a powerful tool that can be programmed to target specific diseases. However, before Moderna began its research, nobody had figured out how to make or use mRNA medicines successfully. ...<ref>Moderna Complaint Para. 42</ref></blockquote>
 
protein needed for a particular disease. This makes mRNA medicines a powerful tool that can be programmed to target specific diseases. However, before Moderna began its research, nobody had figured out how to make or use mRNA medicines successfully. ...<ref>Moderna Complaint Para. 42</ref></blockquote>
   −
<blockquote>Along the way, Moderna encountered many technical challenges as it attempted to develop an entirely new way to treat and prevent disease. The problems that Moderna faced started with the mRNA itself. mRNA is an unstable molecule that is quickly destroyed inside the body. Moderna scientists had to develop novel ways to stabilize mRNA by modifying its chemical structure so that it could be used in vaccines and therapeutics. Moderna also optimized its mRNA platform to make it more effective at producing the proteins needed to fight and prevent disease. <ref>Moderna Complaint Para. 43</ref></blockquote>
+
<blockquote>Along the way, Moderna encountered many technical challenges as it attempted to develop an entirely new way to treat and prevent disease. The problems that Moderna faced started with the mRNA itself. mRNA is an unstable molecule that is quickly destroyed inside the body. Moderna scientists had to develop novel ways to stabilize mRNA by modifying its chemical structure so that it could be used in vaccines and therapeutics. Moderna also optimized its mRNA platform to make it more effective at producing the proteins needed to fight and prevent disease. <ref>Moderna Complaint Para. 43</ref></blockquote> ...
 +
 
 +
<blockquote>48. The genomic sequence for SARS-CoV-2 was first published on January 11, 2020, and, within a matter of days, Moderna took that information to create an mRNA sequence encoding for the virus’s spike protein. The first clinical batch of Moderna’s COVID-19 vaccine was manufactured on February 7, 2020—just four weeks after the genome sequence for SARS-CoV-2 was published. Moderna provided clinical samples to its partners at the NIH. Moderna and the NIH then worked together to conduct clinical trials of Moderna’s vaccine on an expedited basis.
 +
 
 +
49. Moderna’s new mRNA technology dramatically changed the pace of vaccine development. While other leading pharmaceutical companies thought that it could take “several years” or more before a vaccine would be ready, Moderna’s CEO, Stéphane Bancel, predicted in March 2020 that Moderna could have its vaccine in Phase II and III clinical trials in just a “few
 +
months.”<ref>Moderna Complaint Paras. 48-49 (citation to Trump event at the end of Para. 49 omitted).</ref></blockquote>
    
== See also ==
 
== See also ==
Aschlafly
Anthony, Irenaeus, Siteadmin, apieditor, Bureaucrats, Check users, nsAm_Govt_101RO, nsAm_Govt_101RW, nsAm_Govt_101_ta, nsJudgesRO, nsJudgesRW, nsJudges_talkRO, nsJudges_talkRW, nsTeam2RO, nsTeam2RW, nsTeam2_talkRO, nsTeam2_talkRW, oversight, Administrators
126,204

edits

Retrieved from "https://www.conservapedia.com/Special:MobileDiff/1922051"

Navigation menu